CCAM
MLTX icon

Crystal Cove Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Crystal Cove Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$195K Hold
10,000
– – 0.21% 19
2026
Q1 		$186K Buy
+10,000
New +$166K 0.22% 18

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Crystal Cove Asset Management's MLTX Position: Q2 2026 in Review

Crystal Cove Asset Management held its MoonLake Immunotherapeutics (MLTX) position steady in Q2 2026 at 10,000 shares worth $195K. The position accounts for 0.21% of the portfolio, ranked #19.

Crystal Cove Asset Management first reported a position in MLTX in Q1 2026 and has held it in 2 quarters since. 171 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Crystal Cove Asset Management held 10,000 shares of MoonLake Immunotherapeutics worth $195K as of Q2 2026.
  • Crystal Cove Asset Management left its MoonLake Immunotherapeutics share count unchanged in Q2 2026.
  • MoonLake Immunotherapeutics made up 0.21% of Crystal Cove Asset Management's portfolio in Q2 2026, its #19 holding.
  • Crystal Cove Asset Management first reported a position in MoonLake Immunotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 171 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Crystal Cove Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.